Champions Oncology, Inc. Files 10-Q for Period Ending January 31, 2024

TL;DR

<b>Champions Oncology, Inc. has filed its quarterly report (10-Q) for the period ending January 31, 2024.</b>

AI Summary

CHAMPIONS ONCOLOGY, INC. (CSBR) filed a Quarterly Report (10-Q) with the SEC on March 15, 2024. Champions Oncology, Inc. filed a 10-Q report for the period ending January 31, 2024. The company's fiscal year ends on April 30. The filing was made on March 15, 2024. The company's principal business address is in Baltimore, MD. The company was formerly known as Champions Biotechnology, Inc.

Why It Matters

For investors and stakeholders tracking CHAMPIONS ONCOLOGY, INC., this filing contains several important signals. This filing provides an update on the company's financial performance and operational status for the specified quarter. Investors and analysts can use this report to assess the company's financial health and make informed investment decisions.

Risk Assessment

Risk Level: low — CHAMPIONS ONCOLOGY, INC. shows low risk based on this filing. The filing is a standard 10-Q, which is a routine quarterly report and does not contain significant new information that would alter the risk profile.

Analyst Insight

Monitor future 10-Q filings for detailed financial performance and operational updates.

Key Numbers

• 2024-01-31 — Reporting Period End Date (Conformed period of report)
• 2024-03-15 — Filing Date (Filed as of date)
• 0430 — Fiscal Year End (Fiscal year end)

Key Players & Entities

• CHAMPIONS ONCOLOGY, INC. (company) — Filer name
• 20240131 (date) — Conformed period of report
• 20240315 (date) — Filed as of date
• BALTIMORE (location) — Business address city
• MD (location) — Business address state
• Champions Biotechnology, Inc. (company) — Former company name

FAQ

Industry Context

Champions Oncology, Inc. operates in the biological products sector, specifically focusing on oncology-related products.

Regulatory Implications

The filing is made in accordance with the Securities Exchange Act of 1934, requiring public companies to submit quarterly financial reports.

What Investors Should Do

1. Review the full 10-Q filing for detailed financial statements and management discussion.
2. Analyze the company's performance against previous quarters and industry benchmarks.
3. Track any disclosures regarding new developments or strategic initiatives.

Year-Over-Year Comparison

This is a 10-Q filing, representing a quarterly update. Specific comparative data from the previous filing (e.g., 10-K or prior 10-Q) is not detailed in this header information.

Key Financial Figures

• $0.001 — ich Registered Common Stock, par value $0.001 per share CSBR The Nasdaq Stock Market
• $250,000 — it Insurance Corporation ("FDIC") up to $250,000. As of January 31, 2024 and April 30, 2

Filing Documents

• csbr-20240131.htm (10-Q) — 753KB
• csbrq3131202410-qex311.htm (EX-31.1) — 11KB
• csbrq3131202410-qex312.htm (EX-31.2) — 11KB
• csbrq3131202410-qex321.htm (EX-32.1) — 8KB
• 0001628280-24-011279.txt (&nbsp;) — 4215KB
• csbr-20240131.xsd (EX-101.SCH) — 32KB
• csbr-20240131_cal.xml (EX-101.CAL) — 44KB
• csbr-20240131_def.xml (EX-101.DEF) — 138KB
• csbr-20240131_lab.xml (EX-101.LAB) — 392KB
• csbr-20240131_pre.xml (EX-101.PRE) — 265KB
• csbr-20240131_htm.xml (XML) — 525KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Condensed Consolidated Balance Sheets as of January 31, 202 4 (unaudited) and April 30, 20 23 4 Unaudited Condensed Consolidated Statements of Operations for the Three and Nine Months Ended January 31, 202 4 and 202 3 5 Unaudited Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficiency) for the Three and Nine Months Ended January 31, 202 4 and 20 2 3 6 Unaudited Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 31, 202 4 and 20 23 7 Notes to Unaudited Condensed Consolidated Financial Statements 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 18

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 22

Controls and Procedures

Item 4. Controls and Procedures 22

- OTHER INFORMATION

PART II - OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 24

Risk Factors

Item 1A. Risk Factors 24

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 24

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 24

Other Information

Item 5. Other Information 24

Exhibits

Item 6. Exhibits 25 3

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements CHAMPIONS ONCOLOGY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) January 31, 2024 April 30, 2023 (unaudited) ASSETS Current assets: Cash and cash equivalents $ 4,468 $ 10,118 Accounts receivable, net 7,895 8,011 Prepaid expenses and other current assets 835 1,328 Total current assets 13,198 19,457 Operating lease right-of-use assets, net 6,536 7,318 Property and equipment, net 6,533 7,186 Other long-term assets 185 15 Goodwill 335 335 Total assets $ 26,787 $ 34,311 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 4,756 $ 5,334 Accrued liabilities 2,430 2,270 Current portion of operating lease liabilities 1,305 1,208 Other current liability 149 145 Deferred revenue 13,329 12,776 Total current liabilities 21,969 21,733 Non-current operating lease liabilities 6,437 7,391 Other non-current liabilities 439 551 Total liabilities $ 28,845 $ 29,675 Stockholders' equity (deficiency): Common stock, $ .001 par value; 200,000,000 shares authorized; 13,714,099 and 13,558,650 shares issued; and 13,593,766 and 13,544,228 outstanding as of January 31, 2024 and April 30, 2023, respectively 14 14 Treasury stock, at cost ( 708 ) ( 74 ) Additional paid-in capital 83,120 82,013 Accumulated deficit ( 84,484 ) ( 77,317 ) Total stockholders' equity (deficiency) ( 2,058 ) 4,636 Total liabilities and stockholders' equity (deficiency) $ 26,787 $ 34,311 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. 4 CHAMPIONS ONCOLOGY, INC. UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Dollars in Thousands, Except Per Share Amounts) Three Months Ended January 31, Nine Months Ended January 31, 2024 2023 2024 2023 Oncology services revenue $ 12,019 $ 12,773 $ 36,153 $ 40,799 Costs and operating expenses: Cost of oncology services 7,849 7,699 22,151 22,194 Research and development 2,186 3,202 7,494 8,693 Sa

View Full Filing

View this 10-Q filing on SEC EDGAR